David Cork, MD
Cardiovascular Disease · la Jolla, CANPI 1427369271
Payments from drug & device makers
Across 284 payments — averaging $422.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$73K
- Edwards Lifesciences$22K
- Boston Scientific$15K
- Abbott$5K
- Medtronic$3K
- Amgen$406
- plus $2K from 24 others
What the payments were for
- Consulting fees$25,24153%
- Speaking & faculty fees$14,00029%
- Travel & lodging$2,0734%
- Food & beverage$6,11613%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 23 | $72,533 |
| Edwards Lifesciences | 8 | $22,448 |
| Boston Scientific | 35 | $15,083 |
| Abbott | 28 | $5,209 |
| Medtronic(2 entities) | 47 | $2,681 |
| Amgen | 17 | $406 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $297 |
| Biotronik Inc. | 5 | $295 |
| Esperion Therapeutics, Inc. | 12 | $228 |
| Pfizer | 25 | $142 |
| AstraZeneca | 7 | $112 |
| Novartis | 5 | $98 |
| Johnson & Johnson | 6 | $85 |
| Actelion Pharmaceuticals US, Inc. | 19 | $62 |
| Irhythm Technologies, Inc. | 3 | $51 |
| Lantheus Medical Imaging, Inc. | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Novo Nordisk | 1 | $33 |
| Heartflow, Inc. | 2 | $33 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $11 |
| Travere Therapeutics, Inc. | 7 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$14,000
- Confirm Rx$2,816
- AVEIR$1,301
- SAPIEN 3 Ultra RESILIA$173
- Accent Pacemaker$150
- MitraClip$148
- AZURE XT DR MRI SURESCAN$141
- Micra$140
- Assurity Pacemaker$136
- GENERAL BRADY$130
- NA$128
- LINQ II$126
- VIGILANT$120
- SYMPLICITY G3$115
- Repatha$107
How this compares
$120,049 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 328 | $420,370 |
| Repatha SureclickEvolocumab | 227 | $256,182 |
| EntrestoSacubitril/Valsartan | 70 | $80,512 |
| XareltoRivaroxaban | 63 | $77,687 |
| JardianceEmpagliflozin | 61 | $63,845 |
| Praluent PenAlirocumab | 47 | $40,150 |
| FarxigaDapagliflozin Propanediol | 34 | $37,105 |
| NexlizetBempedoic Acid/Ezetimibe | 30 | $25,940 |
| VascepaIcosapent Ethyl | 19 | $18,856 |
| NexletolBempedoic Acid | 14 | $9,360 |
| Ezetimibe | 320 | $9,111 |
| Icosapent Ethyl | 22 | $9,046 |
| Rosuvastatin Calcium | 370 | $5,730 |
| Atorvastatin Calcium | 522 | $5,138 |
| Metoprolol Succinate | 302 | $4,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $420,370328 claims |
| NovartisEntresto | $98 | $80,51270 claims |
| Johnson & JohnsonXarelto | $85 | $77,68763 claims |
| AstraZenecaFarxiga | $112 | $37,10534 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $228 | $35,30044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in la Jolla
- Pam Taubla Jolla$3.2M
- Eric Topolla Jolla$2.2M
- Douglas Gibsonla Jolla$2.2M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.